The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.

Some patients with locally advanced esophageal cancer may be able to safely forgo esophagectomy after CRT, data suggest.

Patients with metastatic NSCLC may benefit from continuing on pembrolizumab-based treatment after progressing on that treatment.

(HealthDay News) — Five leaders at the US Centers for Disease Control and Prevention (CDC) stepped down last week, according to The Associated Press, which confirmed the departures through 2 anonymous ...

The federal government is clawing back $11.4 billion in COVID-19 funding, a move that could affect local and state public health efforts across the US.

Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.

Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.

The objective response rate was 45.4% with SC pembrolizumab and 42.1% with IV pembrolizumab. Subcutaneous (SC) pembrolizumab appears to be non-inferior to standard intravenous (IV) pembrolizumab ...

The Senate has confirmed Dr Jay Bhattacharya as the new director of the NIH and Dr Marty Makary as the new commissioner of the FDA.